Adoptive T Cell Therapy Using Donor Immune Cells to Treat Adenovirus Infection After Stem Cell Transplant

What this Trial Is About

Researchers are evaluating the use of a cell-based immunotherapy called adoptive T cell therapy to treat adenovirus infections in patients who have undergone allogeneic hematopoietic stem cell transplantation HSCT. This experimental therapy aims to help the patients immune system fight the infection by using virus-specific T cells derived from a donor. The study also focuses on understanding the side effects and toxicities related to this therapy. The treatment involves selecting virus-specific T cells from a donors blood using the CliniMACS Prodigy System. Donors who show an immune response to adenovirus undergo leukapheresis to collect cells, which are then processed and infused into the patient as a bolus on day 0. Patients receive a targeted dose based on their weight. Enrollment is staggered with safety observation periods between patients and cohorts to monitor treatment effects. Participants will be closely monitored for safety and effectiveness, including measuring adverse events up to 100 days after infusion and tracking viral and clinical responses within 30 days. The study includes assessments related to treatment timing and cell processing duration. Safety monitoring occurs after specific patient milestones. Total involvement depends on treatment and observation schedules, with detailed follow-up and data collection to evaluate treatment feasibility and outcomes.

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation